Gene Therapy Breakthroughs Offer New Hope for Inherited Retinal Diseases

Gene Therapy Breakthroughs Offer New Hope for Inherited Retinal Diseases

For individuals and families living with inherited retinal diseases (IRDs), the landscape of treatment is rapidly evolving, bringing unprecedented hope. Recent advancements in gene therapy have marked significant milestones, moving from promising research to approved treatments and accelerated development pathways. These breakthroughs signify a new era where genetic conditions once considered untreatable may now have therapeutic solutions, offering the potential to preserve or even improve vision.

First FDA-Approved AAV Gene Therapy for IRD

A monumental achievement occurred in December 2017 with the U.S. Food and Drug Administration (FDA) approval of Luxturna (voretigene neparvovec), the first adeno-associated virus (AAV) gene therapy for a rare retinal disease. Developed by Spark Therapeutics, Luxturna is indicated for patients with biallelic RPE65 gene mutations, which can lead to conditions like Leber congenital amaurosis (LCA) and retinitis pigmentosa. These mutations impair the production of a crucial protein necessary for the retina's proper function, ultimately causing progressive vision loss and, often, total blindness.

Luxturna works by delivering a healthy copy of the RPE65 gene directly into the retinal cells using an AAV vector. Clinical trials, including a Phase III study published in The Lancet in 2017, demonstrated that the therapy improved functional vision, enhancing patients' ability to perform daily activities. While it doesn't restore normal vision, it allows patients to perceive shapes and light, aiding in mobility. The approval of Luxturna was a landmark event, not just for ophthalmology, but for the entire field of medicine, setting a precedent for other gene therapies targeting inherited diseases. The first procedure using Luxturna post-FDA approval was performed in March 2018 at Massachusetts Eye and Ear.

Nightstar's Choroideremia Drug Gains FDA Fast-Track Status

Building on the momentum of Luxturna's approval, Nightstar Therapeutics' gene therapy for choroideremia, NSR-REP1, received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation in June 2018. Choroideremia is a rare, X-linked genetic condition that causes progressive vision loss due to mutations in the CHM gene, leading to the degeneration of the choroid, retinal pigment epithelium, and photoreceptors.

The RMAT designation is a